Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Applied Dna Scns
(NQ:
APDN
)
0.3376
+0.0046 (+1.38%)
Streaming Delayed Price
Updated: 3:58 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Applied Dna Scns
< Previous
1
2
3
4
Next >
The Top 5 Analysts Ranked by Marketbeat and Stocks They Cover
April 09, 2024
Analysts rate the stocks, but who rates the analysts? This is a look at five of the highest-rated analysts tracked by Marketbeat.com based on 12-month ROI.
Via
MarketBeat
Topics
Cannabis
Exposures
Cannabis
Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start
March 18, 2024
Via
ACCESSWIRE
Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress
March 14, 2024
Via
ACCESSWIRE
Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results
February 08, 2024
Via
ACCESSWIRE
Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024
February 05, 2024
Via
ACCESSWIRE
Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results
December 07, 2023
Via
ACCESSWIRE
Applied DNA Extends Application of Linea(TM) IVT Platform to saRNA (self-amplifying mRNA)
November 16, 2023
Via
ACCESSWIRE
Applied DNA Ships First saRNA (self-amplifying mRNA) IVT Template Generated by Linea(TM) DNA Platform
November 09, 2023
Via
ACCESSWIRE
Applied DNA Announces Closing of $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
February 02, 2024
Via
ACCESSWIRE
Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
January 31, 2024
Via
ACCESSWIRE
Applied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow
December 14, 2023
Via
ACCESSWIRE
Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023
December 05, 2023
Via
ACCESSWIRE
Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application
November 28, 2023
Via
ACCESSWIRE
Applied DNA Reports Third Quarter Fiscal 2023 Financial Results and Provides Corporate Update
August 10, 2023
Via
ACCESSWIRE
Applied DNA Reports Second Quarter Fiscal 2023 Financial Results and Provides Corporate Update
May 11, 2023
Via
ACCESSWIRE
Applied DNA Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform Targeting Diseases that Impact High-Value Animals
September 14, 2023
Via
ACCESSWIRE
Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs
September 06, 2023
Via
ACCESSWIRE
Applied DNA Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit
August 29, 2023
Via
ACCESSWIRE
Applied DNA Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production
August 23, 2023
Via
ACCESSWIRE
Applied DNA to Report Third Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, August 10, 2023
August 07, 2023
Via
ACCESSWIRE
Applied DNA Biotherapeutics Subsidiary LineaRx to Participate in Upcoming mRNA Industry Conferences
July 18, 2023
Via
ACCESSWIRE
Applied DNA Acquires RNA Polymerase Developer Spindle Biotech, Launches LineaIVT(TM) Platform to Substantially Improve mRNA Manufacturing and Broaden Market Reach
July 13, 2023
Via
ACCESSWIRE
Applied DNA Announces Presentation at Upcoming Healthcare Investor Conference
June 08, 2023
Via
ACCESSWIRE
Applied DNA to Report Second Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, May 11, 2023
May 03, 2023
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA's CertainT® Supply Chain Traceability Platform Featured in New York Times Article About the Need for Transparency and Compliance in Global Supply Chains Under Recently Passed U.S. Federal Regulation
April 07, 2023
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA Achieves Milestone for Large-Scale linearDNA™ Production, Delivers Largest Single Shipment by Volume to Date
March 29, 2023
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA Submits Validation Package to New York State Department of Health for Approval of Pharmacogenomic (PGx) Assay
March 22, 2023
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA Announces New York State Award Valued at Up To $1.5 Million to Support Establishment of cGMP linearDNA™ Production Capacity on Long Island, New York
February 10, 2023
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA Reports First Quarter Fiscal 2023 Financial Results
February 09, 2023
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA to Report First Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, February 9, 2023
February 02, 2023
From
Applied DNA Sciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.